William Blair Initiates Coverage on Vigil Neuroscience (NASDAQ:VIGL)

William Blair started coverage on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report released on Wednesday, Marketbeat reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for Vigil Neuroscience’s FY2024 earnings at ($2.00) EPS and FY2025 earnings at ($2.30) EPS.

Several other analysts also recently weighed in on VIGL. Guggenheim lowered their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush raised their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.60.

Vigil Neuroscience Stock Performance

Shares of Vigil Neuroscience stock opened at $2.33 on Wednesday. The company has a market capitalization of $95.25 million, a P/E ratio of -1.13 and a beta of 1.65. The company’s fifty day moving average is $3.31 and its two-hundred day moving average is $3.59. Vigil Neuroscience has a 1 year low of $2.08 and a 1 year high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VIGL. Point72 Asset Management L.P. acquired a new position in Vigil Neuroscience during the second quarter worth about $5,940,000. abrdn plc purchased a new stake in shares of Vigil Neuroscience during the third quarter worth about $799,000. Ensign Peak Advisors Inc grew its holdings in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience during the third quarter worth about $442,000. Finally, Vanguard Group Inc. grew its holdings in shares of Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.